Comparable and Complimentary Modalities for Treatment of Small-Sized HCC: Surgical Resection, Radiofrequency Ablation, and Microwave Ablation.
HCC
RFA
microwave
surgical resection
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Jul 2023
29 Jul 2023
Historique:
received:
13
06
2023
revised:
20
07
2023
accepted:
28
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Over the past decade, there has been continual improvement in both ablative and surgical technologies for the treatment of hepatocellular carcinoma (HCC). The efficacy of ablative therapy compared to surgical resection for HCC has not been thoroughly evaluated using multiple large-scale randomized controlled trials. By international consensus, if a patient is eligible, surgery is the primary curative treatment option, as it is believed to confer superior oncologic control. to determine the efficacies of percutaneous ablative therapies and surgical resection (SR) in the treatment of HCC. Data sources, study appraisal, and synthesis methods: A meta-analysis using 5 online databases dating back to 1989 with more than 31,000 patients analyzing patient and tumor characteristics, median follow-up, overall survival, and complication rate was performed. Ablative therapies are suitable alternatives to surgical resection in terms of survival and complication rates for comparable patient populations. For the entire length of the study from 1989-2019, radiofrequency ablation (RFA) produced the highest 5-year survival rates (59.6%), followed by microwave ablation (MWA) (50.7%) and surgical resection (SR) (49.9%). In the most recent era from 2006 to 2019, surgical resection has produced the highest 5-year survival rate of 72.8%, followed by RFA at 61.7% and MWA at 50.6%. Conclusions and key findings: Depending on the disease state and comorbidities of the patient, one modality may offer superior overall survival rates over the other available techniques. Interventional ablative methods and surgical resection should be used in conjunction for the successful treatment of small-sized HCC.
Sections du résumé
BACKGROUND
BACKGROUND
Over the past decade, there has been continual improvement in both ablative and surgical technologies for the treatment of hepatocellular carcinoma (HCC). The efficacy of ablative therapy compared to surgical resection for HCC has not been thoroughly evaluated using multiple large-scale randomized controlled trials. By international consensus, if a patient is eligible, surgery is the primary curative treatment option, as it is believed to confer superior oncologic control.
OBJECTIVE
OBJECTIVE
to determine the efficacies of percutaneous ablative therapies and surgical resection (SR) in the treatment of HCC. Data sources, study appraisal, and synthesis methods: A meta-analysis using 5 online databases dating back to 1989 with more than 31,000 patients analyzing patient and tumor characteristics, median follow-up, overall survival, and complication rate was performed.
RESULTS
RESULTS
Ablative therapies are suitable alternatives to surgical resection in terms of survival and complication rates for comparable patient populations. For the entire length of the study from 1989-2019, radiofrequency ablation (RFA) produced the highest 5-year survival rates (59.6%), followed by microwave ablation (MWA) (50.7%) and surgical resection (SR) (49.9%). In the most recent era from 2006 to 2019, surgical resection has produced the highest 5-year survival rate of 72.8%, followed by RFA at 61.7% and MWA at 50.6%. Conclusions and key findings: Depending on the disease state and comorbidities of the patient, one modality may offer superior overall survival rates over the other available techniques. Interventional ablative methods and surgical resection should be used in conjunction for the successful treatment of small-sized HCC.
Identifiants
pubmed: 37568408
pii: jcm12155006
doi: 10.3390/jcm12155006
pmc: PMC10419984
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
World J Hepatol. 2015 Nov 8;7(25):2578-89
pubmed: 26557950
Clin Radiol. 2017 Feb;72(2):136-140
pubmed: 27890422
J Vasc Interv Radiol. 2016 May;27(5):623-30
pubmed: 27013403
PLoS One. 2013 Oct 17;8(10):e76119
pubmed: 24146824
Surg Endosc. 2014 Dec;28(12):3429-34
pubmed: 24935203
Saudi J Anaesth. 2017 Jan-Mar;11(1):21-25
pubmed: 28217048
Cancer. 1998 Mar 15;82(6):1028-36
pubmed: 9506346
Liver Cancer. 2021 Dec 29;11(3):209-218
pubmed: 35949295
J Surg Oncol. 2002 Dec;81(4):195-202
pubmed: 12451624
Eur J Surg Oncol. 2005 Nov;31(9):986-93
pubmed: 15936169
Beijing Da Xue Xue Bao Yi Xue Ban. 2005 Dec 18;37(6):671-2
pubmed: 16378128
Onco Targets Ther. 2017 Oct 03;10:4829-4839
pubmed: 29042794
Oncotarget. 2017 Apr 25;8(17):28758-28768
pubmed: 28430634
Int J Hyperthermia. 2017 May;33(3):247-254
pubmed: 27649577
Gastroenterology. 2005 Jul;129(1):122-30
pubmed: 16012942
J Hepatol. 2012 Oct;57(4):794-802
pubmed: 22634125
Hepatology. 2022 Jul;76(1):66-77
pubmed: 35007334
J Am Coll Surg. 2010 Apr;210(4):441-8
pubmed: 20347736
Ann Surg. 2021 Apr 1;273(4):656-666
pubmed: 33074898
Ann Surg. 2004 Jul;240(1):102-7
pubmed: 15213625
Jpn J Clin Oncol. 2016 Dec;46(12):1075-1080
pubmed: 27677661
J Hepatol. 2013 Apr;58(4):724-9
pubmed: 23178708
Eur Radiol. 2007 Mar;17(3):684-92
pubmed: 17093964
Hepatogastroenterology. 1995 Jul;42(3):222-9
pubmed: 7590569
World J Surg. 1991 Mar-Apr;15(2):270-85
pubmed: 1851588
Chin J Cancer. 2017 Jan 19;36(1):14
pubmed: 28103953
Ann Surg. 2003 Apr;237(4):536-43
pubmed: 12677151
Radiology. 2005 Apr;235(1):299-307
pubmed: 15731369
Radiology. 2014 Mar;270(3):900-9
pubmed: 24475823
Chin Clin Oncol. 2013 Dec;2(4):39
pubmed: 25841918
World J Gastroenterol. 2015 Feb 7;21(5):1554-66
pubmed: 25663774
Hepatol Res. 2015 Jan;45(1):59-74
pubmed: 24965914
Arch Surg. 1996 Jan;131(1):71-6
pubmed: 8546582
Hepatology. 2000 Dec;32(6):1224-9
pubmed: 11093728
Hepatology. 2009 Nov;50(5):1475-83
pubmed: 19731239
Radiology. 2012 Mar;262(3):1022-33
pubmed: 22357902
Int J Surg. 2013;11(1):77-80
pubmed: 23220487
Ann Surg. 2001 Jul;234(1):63-70
pubmed: 11420484
Surgery. 2002 Jan;131(1 Suppl):S153-8
pubmed: 11821803
J Vasc Interv Radiol. 2015 Jan;26(1):62-8
pubmed: 25446425
BMC Gastroenterol. 2011 Dec 28;11:143
pubmed: 22204311
Radiology. 2005 Mar;234(3):961-7
pubmed: 15665226
J Clin Oncol. 2009 Mar 20;27(9):1485-91
pubmed: 19224838
Hepatogastroenterology. 1998 Aug;45 Suppl 3:1267-74
pubmed: 9730387
J Gastrointest Oncol. 2017 Apr;8(2):337-346
pubmed: 28480072
Hepatogastroenterology. 2002 Jan-Feb;49(43):41-6
pubmed: 11941981
Hepatogastroenterology. 2008 Nov-Dec;55(88):2171-4
pubmed: 19260499
Scand J Gastroenterol. 2008;43(6):727-35
pubmed: 18569991
BMC Gastroenterol. 2010 Jul 09;10:78
pubmed: 20618937
Ann Surg. 2010 Dec;252(6):903-12
pubmed: 21107100
J Hepatol. 2012 Feb;56(2):412-8
pubmed: 21756858
Clin Gastroenterol Hepatol. 2011 Jan;9(1):79-86
pubmed: 20831902
Liver Transpl. 2006 Jun;12(6):934-40
pubmed: 16528715
Gut. 2012 Jul;61(7):1100-1
pubmed: 21997552
World J Gastroenterol. 2015 Mar 14;21(10):2997-3004
pubmed: 25780298
Cancer Control. 2017 Jul-Sep;24(3):1073274817729258
pubmed: 28975836
Hepatol Int. 2011 Jun;5(2):722-9
pubmed: 21484104
Gastroenterol Clin Biol. 1993;17(3):200-6
pubmed: 8392476
Cancer. 2005 Mar 15;103(6):1201-9
pubmed: 15690326
J Am Coll Surg. 2004 Mar;198(3):356-65
pubmed: 14992736
Gastroenterology. 1990 Mar;98(3):733-8
pubmed: 2153601
World J Gastroenterol. 2013 Jul 14;19(26):4106-18
pubmed: 23864773
J Am Coll Surg. 2003 Nov;197(5):753-8
pubmed: 14585409
Ann Surg. 2009 May;249(5):799-805
pubmed: 19387322
Ann Surg. 1993 Apr;217(4):375-84
pubmed: 8385442
Sci Rep. 2016 Sep 13;6:32728
pubmed: 27620527
Ann Surg. 2002 May;235(5):722-30; discussion 730-1
pubmed: 11981219
Hepatology. 2008 Jan;47(1):82-9
pubmed: 18008357
Ann Surg. 2001 Jul;234(1):71-8
pubmed: 11420485